Dermavant Presents Results of Tapinarof in Two P-III Trials for the Treatment of Psoriasis at AAD2021

 Dermavant Presents Results of Tapinarof in Two P-III Trials for the Treatment of Psoriasis at AAD2021

Dermavant Presents Results of Tapinarof in Two P-III Trials for the Treatment of Psoriasis at AAD2021

Shots:

  • The two P-III PSOARING 1 and PSOARING 2 trials involve evaluating Tapinarof (1% dosed, qd) vs vehicle (qd) in 1,025 patients aged 18-75yrs. with plaque psoriasis
  • Results: 2EPs & PRO, @12wks., PASI90 (18.8% and 20.9%) vs (1.6% and 2.5%), ≥4-point NRS improvement (67.5% and 59.7%) vs (46.1 and 31.3%), improvement in QoL as measured by the DLQI, ≥90% reduction in one in five patients in PASI90, improvements in itch measured with PP-NRS
  • Tapinarof is a steroid-free, cosmetically elegant, TAMA topical cream for the treatment of PsO and AD. The data will be included in NDA submission, expected in mid-2021

Click here to­ read full press release/ article | Ref: Business Wire | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post